Lingrui Pharma(600285.SH)

Company Encyclopedia
View More
name
Lingrui Pharma
600285.SH
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, and anesthesiology.
3.027 T
600285.SHMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking29/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE26.04%A
    • Profit Margin21.14%A
    • Gross Margin80.46%A
  • Growth ScoreB
    • Revenue YoY6.15%C
    • Net Profit YoY18.32%B
    • Total Assets YoY17.81%A
    • Net Assets YoY13.15%B
  • Cash ScoreC
    • Cash Flow Margin473.12%C
    • OCF YoY6.15%C
  • Operating ScoreB
    • Turnover0.71B
  • Debt ScoreC
    • Gearing Ratio42.96%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Weight-Loss Drug Prices Drop in China as Patent Expiry Nears

    Prices of weight-loss drugs in China, including Wegovy and Mounjaro, are dropping as patent expirations approach. Wegovy's price has halved to CNY987.48 from CNY1,893.67, while Mounjaro's presale price is now as low as CNY450, down from CNY2,180. Novo Nordisk's price cuts aim to enhance patient compliance. The patent for semaglutide (Wegovy) expires on March 20, prompting domestic firms to prepare generic versions. This price reduction is expected to impact the industry and future weight-loss drug pricing significantly.

    Yicai·
    Yicai·

    Lingrui Pharma: Director Chen Yan plans to reduce holdings by no more than 200,000 shares

    On September 15th, Lingrui Pharma announced that its director Chen Yan plans to reduce his holdings in the company by no more than 200,000 shares, or no more than 0.0353% of the company's total share capital, within three months after the 15 trading days from the date of the announcement due to personal funding needs. The reduction price will be determined based on the market price at the time of the reduction

    Zhitong·
    SH
    600285
    -0.14%
    Zhitong·
    SH
    600285
    -0.14%

    Lingrui Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 474 million yuan, a year-on-year increase of 14.85%

    Lingrui Pharma released its semi-annual report for 2025, with operating revenue of 2.099 billion yuan, a year-on-year increase of 10.14%; net profit attributable to shareholders of the parent company was 474 million yuan, a year-on-year increase of 14.85%; net profit excluding non-recurring gains and losses was 442 million yuan, a year-on-year increase of 12.28%; basic earnings per share were 0.836 yuan

    Zhitong·
    SH
    600285
    -0.14%
    Zhitong·
    SH
    600285
    -0.14%

    Lingrui Pharma released its first-quarter performance, with a net profit attributable to the parent company of 217 million yuan, a year-on-year increase of 13.89%

    According to the Zhitong Finance APP, Lingrui Pharma released its first-quarter report for 2025. The company's first-quarter operating revenue was 1.021 billion yuan, a year-on-year increase of 12.29%; the net profit attributable to shareholders of the listed company was 217 million yuan, a year-on-year increase of 13.89%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 204 million yuan, a year-on-year increase of 12.38%; basic earnings per share were 0.383 yuan/share

    Zhitong·
    SH
    600285
    -0.14%
    Zhitong·
    SH
    600285
    -0.14%

    Lingrui Pharma: The Lingrui Intelligent Logistics Warehousing Platform is officially launched

    According to reports from Lingrui Pharma, on March 1st, the intelligent logistics warehousing platform of Lingrui Pharma officially commenced operations. The Lingrui intelligent logistics warehousing platform is located in the Lingrui Health Industry Park in Xinyang High-tech Zone. The project covers a total area of 3,510 square meters, with a building area of 11,364 square meters and a flat storage area of 10,039 square meters, possessing a strong logistics warehousing capacity to conduct annual pharmaceutical wholesale business worth 2 billion yuan. The launch of this platform marks an important step in Lingrui's digital and intelligent transformation in the pharmaceutical distribution field

    Zhitong·
    SH
    600285
    -0.14%
    Zhitong·
    SH
    600285
    -0.14%
    © 2026 Longbridge｜Disclaimer